Want to see BIAF full AI Analyst Report?
Top Page
bioAffinity Technologies, Inc.
(NASDAQ:BIAF)
Select Model
Select Model
Rating:42Neutral
Price Target:
$6.00
â–²(15.61% Upside)
Action:Reiterated
Date:10/08/26
The score is held down primarily by weak financial performance (large losses, deteriorated margins, and significant negative operating/free cash flow) and bearish technical trends (price below key moving averages with negative MACD). Valuation offers limited support due to negative earnings and no indicated dividend. Corporate events are a relative positive—patent progress, distribution expansion, and reported adoption gains—but they are not enough to offset the current financial and trend risks.
Positive Factors
Commercial adoption
Rapid growth in test volume, ordering physicians, and repeat utilization indicates expanding clinical adoption rather than isolated demand. A broader physician base can increase recurring laboratory-service revenue and strengthen CyPath Lung’s position in lung-nodule assessment over the next several quarters.
Negative Factors
Cash burn
Persistent operating and free-cash-flow deficits show that current operations are not funding the business. Continued cash consumption can require repeated external financing, limit investment flexibility, and make execution of commercialization and product-development plans more dependent on capital availability.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial adoption
Rapid growth in test volume, ordering physicians, and repeat utilization indicates expanding clinical adoption rather than isolated demand. A broader physician base can increase recurring laboratory-service revenue and strengthen CyPath Lung’s position in lung-nodule assessment over the next several quarters.
Read all positive factors
bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.07M
Dividend YieldN/A
Average Volume (3M)6.17M
Price to Earnings (P/E)―
Beta (1Y)-4.71
Revenue Growth-23.17%
EPS Growth67.18%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-120.15
Shares Outstanding1,166,625
10 Day Avg. Volume267,681
30 Day Avg. Volume6,168,250
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.28
Price to Sales (P/S)0.33
P/FCF Ratio-0.22
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue0.55
Enterprise Value/Gross Profit-1.39
Enterprise Value/Ebitda-0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-121.5
Revenue Forecast (FY)$7.31M
bioAffinity Technologies, Inc. Business Overview & Revenue Model
Company Description
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for t...
How the Company Makes Money
bioAffinity Technologies primarily makes money by selling its diagnostic testing products and associated laboratory services, with revenue generated when CyPath® Lung tests are ordered and performed for patients. Earnings are driven by test volume...
bioAffinity Technologies, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.90M | 6.16M | 9.36M | 2.53M | 4.80K | 0.00 |
| Gross Profit | -2.33M | 1.43M | 3.38M | 791.62K | 4.34K | -4.82K |
| EBITDA | -14.72M | -14.32M | -8.33M | -7.63M | -5.61M | -5.32M |
| Net Income | -15.19M | -14.91M | -9.04M | -7.94M | -8.15M | -6.33M |
Balance Sheet | ||||||
| Total Assets | 7.62M | 10.96M | 6.51M | 8.22M | 12.18M | 1.45M |
| Cash, Cash Equivalents and Short-Term Investments | 2.43M | 6.45M | 1.11M | 2.82M | 11.41M | 1.36M |
| Total Debt | 1.44M | 1.16M | 1.50M | 1.58M | 251.75K | 11.36M |
| Total Liabilities | 3.85M | 3.68M | 3.91M | 3.37M | 1.14M | 17.24M |
| Stockholders Equity | 3.77M | 7.28M | 2.60M | 4.86M | 11.04M | -15.79M |
Cash Flow | ||||||
| Free Cash Flow | -11.50M | -9.39M | -7.34M | -6.06M | -4.29M | -2.05M |
| Operating Cash Flow | -11.47M | -9.33M | -7.26M | -6.04M | -4.07M | -2.05M |
| Investing Cash Flow | -91.99K | -60.57K | -79.08K | -2.21M | -219.99K | 0.00 |
| Financing Cash Flow | 13.19M | 14.73M | 5.63M | -344.98K | 14.34M | 3.33M |
bioAffinity Technologies, Inc. Technical Analysis
Negative
5.19
Price Trends
7.48
Negative
12.28
Negative
20.53
Negative
Market Momentum
-0.56
Positive
43.73
Neutral
12.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Negative. The current price of 5.19 is below the 20-day moving average (MA) of 7.33, below the 50-day MA of 7.48, and below the 200-day MA of 20.53, indicating a bearish trend. The MACD of -0.56 indicates Positive momentum. The RSI at 43.73 is Neutral, neither overbought nor oversold. The STOCH value of 12.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIAF.
bioAffinity Technologies, Inc. Risk Analysis
bioAffinity Technologies, Inc. disclosed 77 risk factors in its most recent earnings report. bioAffinity Technologies, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We have received a notice of delisting from Nasdaq due to our failure to maintain the minimum bid price requirement, and there can be no assurance that we will be able to regain compliance or maintain our listing on The Nasdaq Capital Market. Q2, 2026
bioAffinity Technologies, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $9.06M | -0.96 | -224.80% | ― | ― | 98.17% | |
46 Neutral | $5.24M | -0.17 | -170.36% | ― | 38.09% | 54.22% | |
42 Neutral | $7.07M | -0.05 | -257.27% | ― | -23.17% | 67.18% | |
42 Neutral | $2.69M | -0.02 | -524.37% | ― | -92.11% | 86.78% |
* Healthcare Sector Average
BIAF
bioAffinity Technologies, Inc.
6.16
-39.59
-86.54%
NDRA
ENDRA Life Sciences
6.06
-0.39
-6.05%
INBS
Intelligent Bio Solutions
1.59
-9.86
-86.11%
ISPC
iSpecimen
1.10
-38.73
-97.24%
BGLC
BioNexus Gene Lab Corp
1.34
-4.19
-75.77%
bioAffinity Technologies, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
bioAffinity Secures Japanese Patent for CyPath Lung
Positive
Oct 8, 2026
On October 8, 2026, bioAffinity Technologies announced that the Japan Patent Office issued a Notice of Allowance for a patent covering its CyPath Lung test method, which predicts the likelihood of lung cancer using automated flow cytometry and mac...
Business Operations and StrategyFinancial Disclosures
bioAffinity reports surging adoption of CyPath Lung test
Positive
Oct 6, 2026
On October 6, 2026, bioAffinity Technologies reported that sales of its CyPath Lung test more than doubled through the third quarter of 2026 compared with the same period in 2025, driven by growing clinical adoption among high-risk lung cancer pat...
Business Operations and StrategyProduct-Related Announcements
bioAffinity expands CyPath Lung access for U.S. veterans
Positive
Sep 30, 2026
bioAffinity Technologies, Inc., a biotechnology firm developing noninvasive lung disease diagnostics, is centering its commercial strategy on CyPath Lung, an AI-enhanced sputum-based test for early lung cancer detection marketed as a laboratory de...
Business Operations and StrategyProduct-Related Announcements
bioAffinity to Highlight CyPath Lung at NAVREF 2026
Positive
Sep 22, 2026
On September 22, 2026, bioAffinity Technologies announced it would present two posters on its CyPath Lung diagnostic at the NAVREF 2026 Annual Conference, held September 27-30, 2026, in Arlington, Virginia. The meeting convenes leaders from the De...
Business Operations and StrategyProduct-Related Announcements
bioAffinity secures Hong Kong patent for CyPath Lung
Positive
Sep 17, 2026
On September 17, 2026, bioAffinity Technologies announced that Hong Kong’s Intellectual Property Department granted a patent covering its CyPath Lung platform, which predicts the likelihood of lung cancer by using defined antibodies, the por...
Business Operations and StrategyRegulatory Filings and Compliance
bioAffinity Technologies Highlights Investor Presentation at Conference
Neutral
Sep 11, 2026
bioAffinity Technologies prepared a set of presentation materials that its management plans to use in periodic discussions of the company’s operations and performance. These materials are scheduled to be presented at the H.C. Wainwright 28th...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
bioAffinity Regains Nasdaq Compliance, Maintains Capital Market Listing
Positive
Sep 9, 2026
On September 9, 2026, bioAffinity Technologies announced that Nasdaq had confirmed the company regained compliance with the exchange’s minimum bid price and rights/warrants listing rules as of September 8, 2026. The decision cancels a previo...
Business Operations and Strategy
bioAffinity Technologies to Present Corporate Update at Conference
Positive
Sep 3, 2026
On September 3, 2026, bioAffinity Technologies announced that President and CEO Maria Zannes will deliver a corporate update and conduct one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for Se...
Business Operations and StrategyProduct-Related Announcements
bioAffinity advances CyPath Lung for post-treatment surveillance
Positive
Sep 1, 2026
On September 1, 2026, bioAffinity Technologies announced that it is advancing the potential use of its noninvasive CyPath Lung test for surveillance of lung cancer patients who have completed curative-intent treatment. The move targets a growing s...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
bioAffinity Technologies Implements Reverse Stock Split for Nasdaq
Neutral
Aug 20, 2026
On April 30, 2026, bioAffinity Technologies’ shareholders approved an amendment to authorize a reverse split of the company’s common stock, enabling the board to set a ratio between 1-for-2 and 1-for-250. The board subsequently selecte...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Technologies expands CyPath Lung federal distribution
Positive
Aug 18, 2026
On August 18, 2026, bioAffinity Technologies, Inc. announced a nationwide distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business and established supplier of medical and laboratory products to U.S. government healthc...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
bioAffinity Technologies Completes $4 Million Private Placement Financing
Positive
Aug 14, 2026
On August 12, 2026, bioAffinity Technologies entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded warrants and Series A and B warrants tied to 8,462,027 shares of common stock, each warr...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice
Negative
Jul 31, 2026
On July 30, 2026, bioAffinity Technologies received notice from Nasdaq that its shares had closed below $1.00 for 30 consecutive trading days from June 16 through July 29, 2026, putting the company out of compliance with Nasdaq’s minimum bid...
Business Operations and StrategyProduct-Related Announcements
bioAffinity Technologies Highlights CyPath Lung Clinical Framework
Positive
Jul 27, 2026
On July 27, 2026, bioAffinity Technologies published a comprehensive clinical review and white paper by Chief Medical Officer Gordon H. Downie that sets out a practical framework for incorporating CyPath® Lung into the evaluation of pulmonary...
Business Operations and StrategyProduct-Related Announcements
bioAffinity and Pictor partner on lung inflammation diagnostics
Positive
Jul 22, 2026
On July 22, 2026, bioAffinity Technologies announced a collaboration with targeted proteomic platform company Pictor, Inc. to co-develop and commercialize next-generation diagnostic tests that characterize lung inflammation in asthma and COPD pati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.